Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.
Immune checkpoint inhibitors show limited benefit in advanced prostate cancer, highlighting the need for combination strategies.
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is among the leading causes of cancer-related mortality in men worldwide. Immune checkpoint inhibitors (ICIs) have demonstrated a limited effect in mCRPC.
What the study was
- Study design
- Randomized study
- Population
- cancer patients
- Sample size
- 91
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
Score 6/10 [PROMISING_PRELIMINARY]: Randomized study (Journal Article) matched 'Novel therapeutics: immunotherapy, CAR-T'. Components — novelty:1/3, relevance:2/3, design:2/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.